Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386481 | 0.91 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL387444 | 0.88 | MAPT (0.45) | KCNT1 | |
| SCHEMBL390191 | 0.87 | LMNA (0.46) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL390431 | 0.87 | LMNA (0.42) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL14340917 | 0.86 | KCNT1 (0.46) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL387385 | 0.85 | HTT (0.43) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL387321 | 0.85 | KCNT1 (0.46) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL386885 | 0.85 | MAPT (0.41) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL390780 | 0.85 | MAPT (0.52) | HDAC6HDAC1HDAC8HDAC5KCNT1 | |
| SCHEMBL391314 | 0.85 | LMNA (0.41) | HDAC6HDAC1HDAC8HDAC5KCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | claimed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | claimed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | GRIN1, GRM1, GRIN2C | HDAC6 645/4885HDAC1 472/4885HDAC8 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.